Copenhagen, 5 May 2020. Acesion Pharma, a Danish pharmaceutical company developing novel treatments
for atrial fibrillation (AF), the most common cardiac arrhythmia, today announced that it has recruited
Anders Gaarsdal Holst as its Chief Medical Officer (CMO) to succeed Nils Edvardsson, who will continue to
support the company as Medical Adviser. In addition, Acesion Pharma has further strengthened the clinical
team by recruiting Birgitte Vestbjerg as Director Clinical Operations.

Read full press release here.